{"schema_version":"1.0","item":{"schema_version":"1.0","id":"ca-note-sartorius-nine-month-conversion-2026","slug":"sartorius-nine-month-conversion-2026","scope":{"type":"company","slug":"sartorius","label":"Sartorius (SRT)"},"status":"published","published_at":"2026-10-26T05:39:16Z","updated_at":"2026-10-26T05:39:16Z","research_as_of":"2026-10-26","title":"Sartorius shows demand recovery with stronger cash conversion","summary":"Sartorius reported 8.1% constant-currency operational sales growth excluding U.S. tariff compensation for the first nine months of 2026, alongside a 55.2% increase in free cash flow.","what_changed":["Recurring consumables remained a growth driver while bioprocess equipment and instrument demand continued to recover.","Underlying EBITDA margin rose 0.5 percentage points to 30.2%; operating cash flow increased 9.9% and free cash flow reached €310 million as investment declined."],"why_it_matters":"The combination of demand recovery, margin and cash is stronger conversion evidence than a product-capability page. It still does not isolate qualified bioprocess throughput or AI-specific revenue.","confidence":"medium","evidence":[{"label":"Sartorius: nine-month 2026 results","url":"https://www.sartorius.com/en/company/newsroom/corporate-news/2026-nine-month-results-sartorius-group-1886514","source_type":"company_release","primary":true,"supports":"Operational sales growth, margin, cash flow, investment and demand commentary.","as_of":"2026-10-22"}],"human_review_status":"approved","url":"https://constraintalpha.com/research/sartorius-nine-month-conversion-2026","markdown_url":"https://constraintalpha.com/research/notes/sartorius-nine-month-conversion-2026.md"}}